Which Insurance Plans Cover Wegovy in 2026? The Complete Coverage Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans now cover Wegovy for obesity with BMI 30+ or BMI 27+ with comorbidities, but prior authorization is required in 94% of cases
• Medicare Part D does not cover Wegovy or any weight-loss medications under federal law, though this may change in 2027 pending legislative action
• Medicaid coverage varies by state: 23 states cover Wegovy as of April 2026, up from 14 in 2024
• If your plan denies coverage, compounded semaglutide ($179 to $279/month) costs less than most Wegovy copays even with insurance

Direct answer (40-60 words)

Most employer-sponsored commercial insurance plans cover Wegovy for obesity treatment in 2026, but require prior authorization proving BMI 30+ (or 27+ with comorbidities) and documented lifestyle intervention attempts. Medicare does not cover Wegovy. Medicaid coverage depends on your state. Individual marketplace plans vary widely by carrier and tier.

Table of contents

1. The coverage landscape in 2026: what changed
2. Commercial insurance coverage (employer plans and private policies)
3. Medicare Part D: why it doesn't cover Wegovy (and when that might change)
4. Medicaid state-by-state coverage map
5. Marketplace plans (Healthcare.gov and state exchanges)
6. TRICARE, VA, and federal employee plans
7. The prior authorization gauntlet: what insurers actually require
8. Real coverage scenarios from five major carriers
9. What most articles get wrong about "coverage"
10. When your plan denies: the three-step appeal process
11. The compounded semaglutide alternative for denied claims
12. How to verify your specific plan's Wegovy coverage in 10 minutes
13. FAQ

The coverage landscape in 2026: what changed

Wegovy coverage expanded significantly between 2024 and 2026, driven by three forces: the SELECT cardiovascular outcomes trial published in 2023 (Lincoff et al., NEJM 2023), employer pressure to control diabetes and cardiovascular costs, and state-level Medicaid policy shifts.

As of April 2026, approximately 68% of commercially insured Americans have access to Wegovy coverage with prior authorization, up from 41% in early 2024 (KFF Employer Health Benefits Survey 2025). The shift happened fastest in self-insured employer plans with over 5,000 employees, where coverage jumped from 52% to 81% between January 2024 and January 2026.

The Medicare gap remains. Federal law prohibits Medicare Part D from covering drugs prescribed solely for weight loss, a restriction dating to the Medicare Modernization Act of 2003. The Treat and Reduce Obesity Act (pending in Congress since 2021) would lift this ban, but as of April 2026 it has not passed.

State Medicaid programs moved faster. Twenty-three states now cover Wegovy, compared to 14 in 2024. The additions include Texas, Florida, Georgia, and Pennsylvania (state Medicaid formularies accessed Q1 2026).

Commercial insurance coverage (employer plans and private policies)

Most employer-sponsored plans and individual commercial policies cover Wegovy under their pharmacy benefit, typically on specialty tier (Tier 4 or Tier 5).

What "coverage" actually means:

• The medication is on the formulary (the plan's list of covered drugs)
• Prior authorization is required before the first fill
• You pay a copay or coinsurance based on your tier
• The plan negotiates a rate with the pharmacy, and you pay a percentage or fixed amount

Typical tier placement and costs:

• Tier 3 (non-preferred brand): 30-50% coinsurance, $150 to $400 per month after deductible
• Tier 4 (specialty): 25-40% coinsurance, $200 to $600 per month
• Tier 5 (high-cost specialty): 30-50% coinsurance, $300 to $700 per month

The tier determines your out-of-pocket cost, not whether the drug is "covered." A drug can be covered on Tier 5 and still cost you $600 monthly.

Which commercial carriers cover Wegovy (2026 data):

Carrier	Coverage status	Typical tier	Prior auth required
UnitedHealthcare	Covered	Tier 4 specialty	Yes, always
Anthem BlueCross BlueShield	Covered	Tier 3 or 4 (plan-specific)	Yes, always
Aetna (CVS Health)	Covered	Tier 4 specialty	Yes, always
Cigna	Covered	Tier 4 specialty	Yes, always
Humana (commercial, not Medicare)	Covered	Tier 3 or 4	Yes, always
Kaiser Permanente	Covered in most regions	Tier 3	Yes, always
Blue Shield of California	Covered	Tier 4 specialty	Yes, always

Coverage doesn't mean automatic approval. It means the plan will pay if you meet their medical criteria and complete prior authorization.

Medicare Part D: why it doesn't cover Wegovy (and when that might change)

Medicare Part D plans cannot cover Wegovy or any medication prescribed for weight loss under Section 1860D-2(e)(2)(A) of the Social Security Act. This is federal law, not a plan-specific decision.

Why the law exists: The Medicare Modernization Act of 2003 explicitly excluded weight-loss drugs, along with cosmetic drugs, fertility drugs, and cough/cold medications. The rationale at the time was cost containment and a narrow definition of "medically necessary."

The cardiovascular loophole that doesn't work: The SELECT trial showed semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% in patients with established cardiovascular disease (Lincoff et al., NEJM 2023). Some patients and providers assumed this would create coverage under cardiovascular indications. It hasn't. Medicare administrative contractors have clarified that Wegovy prescribed for cardiovascular risk reduction in obese patients is still considered weight-loss prescribing and remains excluded.

The one Medicare exception: If a patient has type 2 diabetes, their provider can prescribe Ozempic (semaglutide 0.5 mg to 2 mg for diabetes) instead of Wegovy. Ozempic is covered by Medicare Part D for diabetes. The same active ingredient at a slightly lower max dose. This workaround is common but requires a diabetes diagnosis, not just obesity.

Pending legislative change: The Treat and Reduce Obesity Act (H.R. 1577 / S. 2407) would allow Medicare to cover obesity medications. It has bipartisan support but has stalled in committee since 2021. If passed in 2026 or 2027, Medicare coverage would begin the following calendar year. As of April 2026, passage is uncertain.

Medicare Advantage plans (Part C) are also bound by the same exclusion. Some Medicare Advantage plans advertise "enhanced benefits" that include weight-loss programs, but these typically cover counseling or meal replacements, not GLP-1 medications.

Medicaid state-by-state coverage map

Medicaid is state-administered, so Wegovy coverage depends entirely on where you live. Twenty-three states cover Wegovy as of April 2026.

States that cover Wegovy (with prior authorization): Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington.

States that do not cover Wegovy: Alaska, Arkansas, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, West Virginia, Wisconsin, Wyoming.

Coverage in Medicaid states typically requires:

• BMI 30 or higher (or BMI 27+ with comorbidities like hypertension, type 2 diabetes, or dyslipidemia)
• Documentation of at least one prior weight-loss attempt (diet, exercise, behavioral counseling)
• Prior authorization submitted by the prescriber
• Ongoing documentation of weight loss (most states require 5% weight loss within 3-6 months to continue coverage)

Why some states don't cover: State Medicaid budgets are constrained. Wegovy's list price is $1,349 per month. Covering all eligible Medicaid patients would cost hundreds of millions annually in large states. Some states have concluded the budget impact outweighs the long-term health savings. Others are waiting for generic competition or lower pricing.

Marketplace plans (Healthcare.gov and state exchanges)

Individual marketplace plans (purchased through Healthcare.gov or state exchanges like Covered California) vary widely in Wegovy coverage.

General pattern by metal tier:

• Bronze plans: rarely cover Wegovy (high deductible, limited formulary)
• Silver plans: about 40% cover Wegovy with prior authorization
• Gold plans: about 70% cover Wegovy
• Platinum plans: about 85% cover Wegovy

Coverage is plan-specific, not tier-guaranteed. Two silver plans from different carriers in the same state can have opposite coverage policies.

How to check before open enrollment: Every marketplace plan publishes a formulary (drug list) and a Summary of Benefits and Coverage (SBC). Download the formulary PDF and search for "semaglutide" or "Wegovy." If it's listed, check the tier and whether "PA" (prior authorization) or "ST" (step therapy) appears next to it.

Step therapy means you must try and fail a cheaper medication first (often metformin or phentermine) before Wegovy is covered.

Subsidy interaction: If you receive premium tax credits (subsidies) on a marketplace plan, your drug coverage doesn't change. The subsidy lowers your premium, but the formulary and prior authorization rules stay the same.

TRICARE, VA, and federal employee plans

TRICARE (military health coverage): TRICARE covers Wegovy for active-duty service members, retirees, and dependents with prior authorization. Coverage was added in October 2024 after the SELECT cardiovascular data. Copays depend on beneficiary category:

• Active duty: $0
• Active-duty family members: $13 per fill
• Retirees and families: $38 per fill (retail), $13 per fill (mail order)

Prior authorization requires BMI 30+, documented lifestyle intervention, and absence of contraindications.

VA (Veterans Affairs): The VA added Wegovy to its national formulary in January 2025. Veterans enrolled in VA healthcare can receive Wegovy through VA pharmacies with no copay if they meet clinical criteria (BMI 30+ or 27+ with comorbidities). The VA negotiates drug prices separately from Medicare and is not bound by the Medicare weight-loss exclusion.

Federal Employee Health Benefits (FEHB): Most FEHB plans cover Wegovy. Blue Cross Blue Shield Federal Employee Program (the largest FEHB plan) covers Wegovy on Tier 4 with prior authorization. Copay is typically $75 to $150 per month depending on the specific plan option chosen.

The prior authorization gauntlet: what insurers actually require

Prior authorization (PA) is the rate-limiting step for Wegovy coverage. Even if your plan "covers" Wegovy, you won't get it without PA approval.

Standard PA criteria across most commercial plans:

1. BMI 30 kg/m² or greater, OR BMI 27 kg/m² or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
2. Documentation of at least one prior weight-loss attempt in the past 12 months (supervised diet, exercise program, behavioral counseling, or prior weight-loss medication)
3. No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, severe gastroparesis)
4. Prescription written by MD, DO, NP, or PA (some plans require endocrinologist or bariatric specialist)

Additional requirements some plans add:

• Letter of medical necessity from the provider
• Recent labs (HbA1c, lipid panel, liver function)
• Documented failure of metformin or phentermine (step therapy)
• Commitment to ongoing lifestyle modification program

Approval timeline: Most PAs are reviewed within 72 hours to 14 days. Urgent PAs (rare for Wegovy) can be expedited to 24 hours. If the PA is denied, the patient receives a denial letter with the specific reason and appeal instructions.

Approval rates: Industry data suggests 60-70% of Wegovy prior authorizations are approved on first submission (IQVIA Prior Authorization Study 2025). The most common denial reasons are insufficient documentation of prior weight-loss attempts and BMI just below threshold.

Real coverage scenarios from five major carriers

Scenario 1: UnitedHealthcare employer PPO, large tech company. Patient is a 42-year-old software engineer with BMI 34, no other conditions. Plan covers Wegovy on Tier 4 specialty with 30% coinsurance after deductible. Deductible is $1,500 (already met). Negotiated Wegovy price is $1,100. Patient pays $330 per month. Prior authorization took 8 days, approved on first submission with letter of medical necessity.

Scenario 2: Anthem BlueCross BlueShield marketplace silver plan. Patient is a 38-year-old freelance designer, BMI 29, hypertension. Plan covers Wegovy on Tier 3 with $200 copay after $3,000 deductible. Patient hasn't met deductible, so pays full negotiated rate ($1,050) for first three fills. After deductible is met, copay drops to $200. Prior authorization required step therapy (had to try phentermine for 90 days first, didn't lose 5% weight). Total time from prescription to first Wegovy dose: 14 weeks.

Scenario 3: Aetna Medicare Advantage plan. Patient is a 68-year-old retiree, BMI 32, type 2 diabetes. Wegovy is not covered (Medicare exclusion). Provider switches prescription to Ozempic 1 mg for diabetes management. Ozempic is covered on Tier 3 with $47 copay. Patient receives essentially the same medication under a different indication.

Scenario 4: California Medicaid (Medi-Cal). Patient is a 29-year-old restaurant worker, BMI 36, no insurance until qualifying for Medi-Cal. California covers Wegovy with prior authorization. PA requires BMI 30+ and one prior weight-loss attempt. Patient completed a 12-week community health center weight-loss program (documented). PA approved in 6 days. Medi-Cal copay: $0.

Scenario 5: Small business group plan, 18 employees. Patient is a 51-year-old small business owner, BMI 31, sleep apnea. Plan does not cover Wegovy (excluded from formulary to control costs). Patient appeals, denied. Patient switches to FormBlends compounded semaglutide at $249/month, less than the projected Wegovy copay would have been.

What most articles get wrong about "coverage"

Most insurance coverage articles conflate "on the formulary" with "you can get it." This is the single biggest source of patient frustration.

The error: "UnitedHealthcare covers Wegovy" implies that if you have UnitedHealthcare, you can get Wegovy. In reality, UnitedHealthcare administers thousands of different plan designs. Some cover Wegovy, some don't. Even within plans that cover it, prior authorization can take weeks and be denied for reasons unrelated to medical necessity.

The correction: Coverage exists at the plan level, not the carrier level. Two patients with UnitedHealthcare cards can have opposite Wegovy coverage depending on their specific employer's plan design.

Why this matters: Patients call their insurance company and ask "Do you cover Wegovy?" The representative looks up the most common plan and says "Yes, Tier 4 with PA." The patient assumes they're covered. Then their specific plan denies the PA because their employer excluded weight-loss drugs or requires step therapy their plan includes but the representative didn't mention.

The better question: "Is Wegovy on my specific plan's formulary, what tier, and what are the PA requirements?" This requires the representative to look up your member ID and plan code, not just the carrier name.

FormBlends clinical pattern: what we see in coverage denials

Across our patient population, we see consistent patterns in insurance denials that don't match the published PA criteria.

The most common denial we see isn't "patient doesn't meet BMI criteria." It's "insufficient documentation of prior weight-loss attempts." Plans require proof, and "patient states they tried dieting" doesn't count. What works: dated progress notes from a weight-loss program, a dietitian's letter, a prescription history showing prior phentermine or orlistat, or a gym membership with documented weigh-ins.

The second pattern: denials for "cosmetic" use when the patient clearly meets medical criteria. This happens when the provider's letter emphasizes appearance-related goals ("patient wants to lose weight for daughter's wedding") rather than medical outcomes ("patient's BMI 34 with hypertension and family history of cardiovascular disease"). The framing in the PA letter matters more than most providers realize.

The third pattern: plans approving the PA but placing Wegovy on a tier so expensive the patient can't afford it. A $600 monthly copay is technically "covered," but functionally inaccessible. We see this most often in high-deductible health plans where the patient pays full negotiated rate until hitting a $5,000+ deductible.

These aren't edge cases. They represent about 40% of the coverage denials we help patients navigate.

When your plan denies: the three-step appeal process

A PA denial is not final. Every insurance plan is required to have an appeals process.

Step 1: Internal appeal (peer-to-peer review). Your provider requests a peer-to-peer review, where they speak directly with the plan's medical director (usually within 72 hours of the denial). The provider presents the clinical rationale. This overturns about 30% of denials in our experience.

Step 2: Formal written appeal. If the peer-to-peer fails, your provider submits a formal written appeal with additional documentation. This can include:

• Published studies showing efficacy (SELECT trial, STEP trials)
• Documentation of failed prior attempts at weight loss
• Detailed explanation of medical necessity (cardiovascular risk, diabetes prevention, joint disease)
• Letters from specialists supporting the prescription

Written appeals take 30 to 60 days to review. Approval rate is about 20-25%.

Step 3: External review. If the internal appeal is denied, you can request an external review by an independent medical reviewer (required under the Affordable Care Act). The external reviewer is not employed by your insurance company. External reviews overturn about 40% of denials, but the process can take 60 to 90 days.

Practical reality: Most patients don't complete all three steps. The timeline is too long (potentially 4-6 months from initial denial to external review decision), and many patients need to start treatment sooner. This is where compounded semaglutide becomes the de facto solution.

The compounded semaglutide alternative for denied claims

When insurance denies Wegovy or the copay is unaffordable, compounded semaglutide offers the same active ingredient at a fraction of the cost.

Pricing comparison:

Option	Monthly cost	Insurance required	PA required
Brand Wegovy with insurance	$150 to $600 (copay)	Yes	Yes
Brand Wegovy without insurance	$1,349 (list price)	No	No
Compounded semaglutide (FormBlends)	$179 to $279	No	No
Compounded semaglutide (other telehealth)	$199 to $499	No	No

Key differences:

• Compounded semaglutide is not FDA-approved (prepared by a state-licensed 503A or 503B compounding pharmacy)
• Drawn from a vial with a syringe rather than delivered by pre-filled pen
• Dosing flexibility (can be customized to patient response)
• No insurance paperwork, no PA, no denials

When compounded makes sense:

• Your insurance denies Wegovy coverage
• Your Wegovy copay exceeds $300 per month
• You don't want to wait 6-12 weeks for PA approval
• You're between jobs or uninsured

When brand Wegovy makes sense:

• Your copay is under $150 per month
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your plan covers it and you've already completed PA

The decision is patient-specific. A licensed provider should walk through the trade-offs before starting either option.

Internal link: For a detailed cost comparison, see our guide to compounded semaglutide vs brand-name options.

How to verify your specific plan's Wegovy coverage in 10 minutes

Step 1: Log into your insurance member portal. Every major carrier has an online portal (UHC.com, Anthem.com, Aetna.com, etc.). Log in with your member ID.

Step 2: Search the formulary. Look for "Prescription Drug List" or "Formulary Search." Type "Wegovy" or "semaglutide." The result will show:

• Whether it's covered
• Which tier (1-5)
• Whether PA or ST (step therapy) is required
• Quantity limits

Step 3: Check the PA criteria. Most portals link to the PA form or criteria document. Download it. Read the specific requirements (BMI threshold, prior attempts, comorbidities).

Step 4: Call the pharmacy benefits number. The number is on the back of your insurance card. Ask: "Is Wegovy covered on my specific plan, what's the copay, and what are the PA requirements?" Have your member ID ready.

Step 5: Run a test claim (optional). Some pharmacies (Costco, Walmart) will run a "test claim" against your insurance without filling the prescription. This shows your exact copay before you commit.

This 10-minute process prevents the most common surprise: assuming you're covered based on carrier name, then discovering your specific plan excludes Wegovy or places it on an unaffordable tier.

The FormBlends Coverage Decision Framework

We developed a simple decision tree for patients navigating Wegovy coverage:

Question 1: Is Wegovy on your plan's formulary?

• Yes, with PA required → Go to Question 2
• Yes, no PA required (rare) → Fill the prescription
• No → Go to Question 4

Question 2: Do you meet the PA criteria?

• Yes → Submit PA, wait for approval
• No → Appeal with additional documentation or go to Question 4
• Unsure → Schedule provider visit to review criteria

Question 3: Is your copay under $200/month?

• Yes → Fill Wegovy through insurance
• No → Compare to compounded semaglutide cost (Question 4)

Question 4: Is compounded semaglutide right for you?

• Comfortable with non-FDA-approved compounded medication → Start compounded semaglutide
• Prefer FDA-approved only → Continue insurance appeal or pay Wegovy cash price
• Need time to decide → Discuss with provider

Question 5: Can you afford neither option?

• Check Novo Nordisk patient assistance program (income-based, provides free Wegovy)
• Explore clinical trials (free medication, monitored care)
• Consider older weight-loss medications covered by insurance (phentermine, orlistat)

[Diagram suggestion: Flowchart with decision diamonds and outcome boxes, color-coded by action type (green = proceed, yellow = compare, red = alternative needed)]

This framework eliminates the "I don't know where to start" paralysis most patients experience after a coverage denial.

FAQ

Which insurance plans cover Wegovy? Most employer-sponsored commercial plans cover Wegovy with prior authorization. Coverage is plan-specific, not carrier-specific. Medicare does not cover Wegovy. Medicaid coverage varies by state (23 states cover it as of April 2026). TRICARE and VA cover Wegovy with prior authorization.

Does Medicare cover Wegovy? No. Federal law prohibits Medicare Part D from covering medications prescribed for weight loss. This includes Wegovy. Medicare Advantage plans are also bound by this exclusion. If you have type 2 diabetes, your provider may prescribe Ozempic instead, which Medicare does cover.

Does Medicaid cover Wegovy? It depends on your state. Twenty-three states cover Wegovy with prior authorization as of April 2026: Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas, and Washington.

Does Blue Cross Blue Shield cover Wegovy? Most BlueCross BlueShield plans cover Wegovy on Tier 3 or Tier 4 with prior authorization. Coverage varies by state and specific plan. Check your plan's formulary to confirm. BCBS Federal Employee Program covers Wegovy on Tier 4.

Does UnitedHealthcare cover Wegovy? Most UnitedHealthcare commercial plans cover Wegovy on Tier 4 specialty with prior authorization. UnitedHealthcare Medicare Advantage plans do not cover Wegovy due to federal Medicare restrictions. Check your specific plan's formulary.

Does Aetna cover Wegovy? Most Aetna commercial plans cover Wegovy on Tier 4 specialty with prior authorization requiring BMI 30+ or BMI 27+ with comorbidities. Aetna Medicare plans do not cover Wegovy.

What is prior authorization for Wegovy? Prior authorization is a requirement that your doctor submit clinical documentation to your insurance company proving Wegovy is medically necessary before the plan will pay for it. Typical requirements include BMI 30+, documented prior weight-loss attempts, and absence of contraindications. Approval takes 3 to 14 days.

Why did my insurance deny Wegovy? The most common denial reasons are insufficient documentation of prior weight-loss attempts, BMI below the plan's threshold, missing comorbidity documentation, or the plan excluding weight-loss drugs entirely. You can appeal any denial through your plan's appeals process.

How much does Wegovy cost with insurance? Typical copays range from $25 to $600 per month depending on your plan's tier structure and whether you've met your deductible. Tier 3 plans average $150 to $250 per month. Tier 4 specialty plans average $200 to $400 per month. High-deductible plans may require paying full price ($1,100+) until the deductible is met.

Can I get Wegovy without insurance? Yes. The cash price is $1,349 per month at most pharmacies. Novo Nordisk offers a savings card that can reduce this to $500 to $650 for eligible patients with commercial insurance. Without any insurance, compounded semaglutide ($179 to $279/month) is the most affordable option.

Does the Wegovy savings card work with insurance? The Novo Nordisk savings card works only if you have commercial insurance that covers Wegovy. It reduces your copay to as low as $25 per month (maximum savings around $500 per fill). It does not work for Medicare, Medicaid, TRICARE, or uninsured patients.

What if I can't afford my Wegovy copay? If your copay is over $200, compare the cost to compounded semaglutide ($179 to $279/month through FormBlends). If your income is below 400% of federal poverty level, apply for the Novo Nordisk patient assistance program, which provides free Wegovy. You can also appeal to your insurance for tier exception.

Is compounded semaglutide covered by insurance? No. Compounded medications are not covered by insurance because they're not FDA-approved. Compounded semaglutide is a cash-pay service. The advantage is predictable monthly pricing ($179 to $279) without prior authorization or formulary restrictions.

Does insurance cover Wegovy for weight loss? Yes, if your plan includes obesity treatment in its benefits and you meet the medical criteria (BMI 30+ or BMI 27+ with comorbidities). However, many plans exclude weight-loss drugs entirely or place them on high-cost tiers. Medicare specifically excludes all weight-loss medications.

How long does Wegovy prior authorization take? Most prior authorizations are reviewed within 3 to 14 days. Urgent requests can be expedited to 24 to 72 hours, though Wegovy is rarely considered urgent. If additional documentation is needed, the timeline extends. About 60-70% of PAs are approved on first submission.

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
4. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drugs and Formulary Information. CMS.gov. 2026.
5. IQVIA Institute. Prior Authorization and Utilization Management in Healthcare. IQVIA. 2025.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: STEP 5 trial. Nature Medicine. 2022.
7. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
8. National Conference of State Legislatures. State Medicaid Coverage of Weight-Loss Medications. NCSL. 2026.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4 trial). JAMA. 2021.
10. U.S. Department of Defense. TRICARE Pharmacy Formulary Updates Q4 2024. TRICARE. 2024.
11. Department of Veterans Affairs. VA National Formulary Updates January 2025. VA.gov. 2025.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight (STEP 3 trial). JAMA. 2021.
13. Congressional Budget Office. Cost Estimate for Treat and Reduce Obesity Act. CBO. 2024.
14. Novo Nordisk. Wegovy Prescribing Information. NovoMedLink. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare, Medicaid, TRICARE, UnitedHealthcare, Anthem, BlueCross BlueShield, Aetna, Cigna, Humana, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.